Biomedical Engineering Reference
In-Depth Information
H
H
NH
2
.HCl
NH
2
.HCl
H
H
CH
3
H
H
Amantadine
Rimantadine
HO
OH
H
O
O
OH
O
O
HN
HN
O
O
O
OH
CH
3
NH
2
CH
3
NH
NH
2
Oseltamivir
NH
Zanamivir
O
H
2
N
N
N
N
HO
O
HO
OH
Ribavirin
FIGURE 24.16
Structures of a number of anti-inl uenza-virus compounds.
Principal indication(s)
: Inl uenza A virus infections (prevention and early therapy). Also used in the
treatment of Parkinson's disease.
Administered
: Orally at 200 mg/day (two times a 100 mg capsule).
24.5.2 R
IMANTADINE
Structure
(Figure 24.16):
α
-Methyltricyclo[3.3.1.1.
3,7
]decane-1-methanamine hydrochloride,
α
-methyl-1-adamantanemethylamine HCl, Flumadine
®
.
Activity spectrum
: Inl uenza A virus.
Mechanism of action
: As for amantadine.
Principal indication(s)
: Inl uenza A virus infections (prevention and early therapy).
Administered
: Orally at 300 mg/day (two times 150 mg).
24.5.3 Z
ANAMIVIR
Structure
(Figure 24.16): 4-Guanidino-2,4-dideoxy-2,3-didehydro-
N
-acetylneuraminic acid,
5-acetylamino-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-d-glycero-d-galacto-
non-2-enonic acid, CG 167, Relenza
®
.
